-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743

Benzinga·11/04/2026 16:45:14
Listen to the news
Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.